论文部分内容阅读
目的:探讨川芎嗪对不稳定型心绞痛患者血浆超敏C反应蛋白和脂蛋白相关磷脂酶A2的影响。方法:将2016年1月—2016年10月在本院心内科治疗的100例不稳定型心绞痛患者随机分为两组,对照组50例采用常规治疗方法,在此基础上观察组50例加用川芎嗪注射液治疗,比较两组患者的治疗效果、发病频率和发病时间、各项实验室指标情况。结果:观察组用药后治疗有效率为94%,显著高于对照组的78%,差异有统计学意义(P<0.05);观察组治疗后心绞痛发作次数及心绞痛持续时间均明显较对照组减少,差异有统计学意义(P<0.05);观察组治疗后血浆超敏C反应蛋白(hs-CRP)、脂蛋白相关磷脂酶A2(Lp-PLA2)、心肌肌钙蛋白I(cTnI)明显较对照组降低,差异有统计学意义(P<0.05)。结论:川芎嗪对不稳定型心绞痛患者治疗效果显著,能有效减少心绞痛的发作,降低炎症反应对心肌损伤,提高心肌修复能力,具有积极的临床意义。
Objective: To investigate the effects of ligustrazine on plasma high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 in patients with unstable angina pectoris. Methods: One hundred cases of unstable angina pectoris treated in our hospital from January 2016 to October 2016 were randomly divided into two groups, 50 cases in the control group were treated by conventional method, on the basis of which 50 cases in the observation group Treated with ligustrazine injection, the therapeutic effect, frequency of onset and onset time of the two groups of patients were compared, and the laboratory indexes were also obtained. Results: The effective rate of treatment group was 94%, significantly higher than 78% of control group, the difference was statistically significant (P <0.05); the number of angina attacks and duration of angina pectoris in observation group were significantly decreased (P <0.05). The levels of plasma hs-CRP, Lp-PLA2 and cTnI in the observation group were significantly higher than those in the control group The control group decreased, the difference was statistically significant (P <0.05). CONCLUSION: Ligustrazine has a significant therapeutic effect on patients with unstable angina pectoris, which can effectively reduce the incidence of angina pectoris, reduce the inflammatory reaction on myocardial injury and improve the ability of myocardial repair, which has a positive clinical significance.